- Global Pharma News & Resources

Atypical Antipsychotic Market is Booming Worldwide by 2028 | Growth, Share, Demand and Analysis Forecasts

The increasing prevalence of lifestyle-related problems associated with mental disorders, and increasing number of bipolar disorders are booming the growth of the market from the last decade. Rising number of patients suffering from major depressive disorders, bipolar disorders, schizophrenia and other mental disorders are fueling the need for atypical antipsychotic drugs, and in turn driving the growth of the global atypical antipsychotic market.  Early prevention of the mental disorders plays an important role in minimizing the damage caused due to mental disorders.  Atypical antipsychotic drugs are available in the hospital pharmacies, e-commerce, retail pharmacies and drug stores. Atypical antipsychotics are usually prescribed to provide treatment for negative symptoms of psychosis such as hallucinations, and delusions, among others. Atypical antipsychotics produce a sedative or tranquilizing effect. Both typical and atypical antipsychotics are used to treat symptoms of schizophrenia and bipolar disorders. However, atypical antipsychotics have a broad spectrum of action than typical antipsychotics and are used to treat depressions that do not respond to antidepressant medications alone. Some of the atypical antipsychotic drugs are also used for severe anxiety, persistent hiccups, problems with balance and nausea. It can also be given in agitation and some psychotic experiences in dementia. Atypical antipsychotics are available in various dosage forms, however, the commonly prescribed dosage forms are tablets or liquids. Atypical antipsychotic drugs do not cure psychosis but can control symptoms such as delusions, hallucinations, including paranoia and hearing voices, etc. They are also helpful in conditions such as anxiety and serious agitation, for example, feeling threatened. They also cure incoherent speech, muddled thinking, confusion, violent behaviour, and mania. 

Evolution of Atypical Antipsychotic Drugs

The introduction of atypical antipsychotic drugs in the market has changed the scenario of the serious mentally disorders.  Patients suffering from mental disorders are no longer needed to be physically restrained and could be managed with drug treatment and medication. The introduction of atypical antipsychotic drugs was a breakthrough in psychiatric care. Clozaril (clozapine) was the first FDA-approved atypical antipsychotic drug, which was used for the treatment of schizophrenia. Sandoz Pharmaceutical Corporation was the inventor of Clozaril drug. Clozaril is an effective drug for schizophrenia without any extrapyramidal symptoms (EPS) or side effects. According to the New York Times, Clozaril was one of the world’s most expensive drugs. Janssen Pharmaceutical division of Johnson and Johnson was the second company with another atypical antipsychotic drug called Risperdal (risperidone), which was approved by the FDA in 1993. In 2003, the drug was approved to treat bipolar disorders. The third atypical antipsychotic drug called Zyprexa (olanzapine) was launched by Eli Lily in the market. In 1996, Zyprexa was given the FDA approval after the clinical studies. Later on, many atypical antipsychotic drugs were introduced in the market.

To remain ahead of your competitors, request for a sample –

Atypical Antipsychotic Market Assessment by Indication Type

Atypical Antipsychotics Drugs

Some of the commonly used atypical antipsychotics drugs for the treatment of mental disorders are Ziprasidone, Paliperidone, Aripiprazole, Risperidone, Quetiapine, and others. A significant portion of the market has been covered by Quetiapine and Risperidone because they are inexpensive drugs used to treat schizophrenia and bipolar disorders. Moreover, the awareness towards mental disorders is primarily important, which leads to strong positioning of the drugs in the overall market.

Regional Market Outlook

Geographically, the global atypical antipsychotic market is segmented into seven key regions viz.  North America, Latin America, Western Europe, Eastern Europe,  Asia Pacific excluding Japan, Japan, and the Middle East & Africa. North America will continue to dominate the global market due to large patient pool and high treatment rates. Europe is expected to hold second highest share in the global atypical antipsychotic market owing to increasing R&D efforts by the key players in the region. Asia Pacific is expected to have delayed growth in the atypical antipsychotics market. According to the Medical Council of India, many Indians are diagnosed with psychological disorders but due to lack of awareness, they are being untreated.

Competition Outlook

Examples of some of the key players identified in the global atypical antipsychotic market are GlaxoSmithKline Plc., Johnson and Johnson, Pfizer Inc., Eil Lilly and Company, Bristol-Myers Squibb Company, Allergan Plc., Cardinal Health Inc., Sanis Health Inc. , Ranbaxy Inc. (Sun Pharmaceutical Industries Ltd.), Novartis AG,  etc.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert –

Small-Scale Manufacturers/Providers:

  • Ranbaxy Inc. (Sun Pharmaceutical Industries Ltd.

Medium-Scale Manufacturers/Providers

  • Cardinal Health Inc.
  • Sanis Health Inc.

Large-Scale Manufacturers/Providers

  • Bristol-Myers Squibb Company
  • Novartis AG
  • Allergan Plc.
  • GlaxoSmithKline Plc.
  • Johnson and Johnson
  • Pfizer Inc.
  • Eil Lilly and Company

 Key data points covered in report

The report covers exhaustive analysis on:

  • Atypical Antipsychotic Market by test type, end user and region
  • Regional level market analysis of North America, Latin America, Europe, Asia Pacific Excluding Japan, Japan, Middle East & Africa by test type, end user segments and country
  • Atypical Antipsychotic Market Dynamics & Opportunity Assessment
  • Historical Actual Market Size, 2013 – 2017
  • Atypical Antipsychotic Market Size & Forecast 2018 – 2028
  • Organ Function Assays Agents Current Trends/Issues/Challenges
  • Competition & Companies involved

For in-depth insights, Download a PDF Brochure –

Market Segmentation 

By Drug Class

  • Risperidone
  • Olanzapine
  • Quetiapine
  • Ziprasidone
  • Aripiprazole
  • Paliperidone
  • Lurasidone

By Indication

  • Bipolar I Disorder
  • Schizophrenia
  • Schizoaffective Disorder
  • Major Depressive Disorder (MDD)

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Drug Store
  • E-commerce

Editor Details

Last Updated: 04-Mar-2022